Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Per Lav Madsen1,2, Annemie Stege Bojer3,4, Martin Sørensen3

  • 1Kardiologisk Afdeling, Københavns Universitetshospital - Herlev og Gentofte Hospital.

Ugeskrift for Laeger
|October 28, 2022
PubMed
Summary

Overweight and type 2 diabetes accelerate cardiovascular disease, causing heart stiffening and failure. Early detection of diabetic cardiomyopathy, marked by cardiac changes, is crucial for metabolic syndrome treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ontological Analysis of Brain Proteostasis Highlights the Sex-Dependent Trajectory of ApoE Isoform-Specific Regulation.

bioRxiv : the preprint server for biology·2026
Same author

Dietary Medium-Chain Triacylglycerols Preserve Cardiac Function During High-Fat Feeding and Improve Ketolysis Capacity in Mice.

JACC. Heart failure·2026
Same author

The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.

BMC medicine·2026
Same author

The Effect of Empagliflozin on Left Ventricular Mass and Volumes in Older Adult Individuals With Overweight and High Risk of Heart Failure: The Empire Prevent Cardiac Trial.

Journal of cardiac failure·2026
Same author

Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.

Diabetes care·2026
Same author

Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks' treatment with semaglutide.

Cardiovascular diabetology. Endocrinology reports·2026

Area of Science:

  • Cardiology
  • Endocrinology
  • Medical Imaging

Context:

  • Overweight and diabetes mellitus (DM) are significant risk factors for premature cardiovascular disease.
  • Diabetes can lead to circulatory stiffening and heart failure with preserved ejection fraction, even without ischemic heart disease.
  • Type 2 DM is associated with cardiac structural changes.

Purpose:

  • To highlight the cardiac manifestations of diabetes.
  • To emphasize the importance of early detection and intervention in diabetic cardiomyopathy.
  • To identify key phenotypical changes in the diabetic heart as potential therapeutic targets.

Summary:

  • Diabetes and overweight contribute to early cardiovascular complications.
  • Magnetic resonance imaging reveals cardiac hypertrophy, vascular rarefaction, and fibrosis in type 2 DM patients.

Related Experiment Videos

  • These changes indicate "diabetic cardiomyopathy," which develops over years.
  • Impact:

    • Early identification of diabetic cardiomyopathy is essential for effective management of the metabolic syndrome.
    • Targeting cardiac hypertrophy, vascular rarefaction, and fibrosis may offer new avenues for intervention.
    • Understanding these phenotypical changes can lead to improved patient outcomes and prevention of heart failure.